Cystic fibrosis (CF) is a progressive life threatening multisystem genetic disease which affects the CF transmembrane conductance regulator channel. Respiratory causes remain the most common mortality in CF. With the onset of newborn screening, initiating treatments both for prophylaxis and disease management, optimizing nutritional support, and developing therapies targeting CF transmembrane conductance regulator protein, this has significantly changed the face of managing this devastating disease. Bronchoscopy and related procedures such as bronchoalveolar lavage (BAL), transbronchial biopsies, and protected brush sampling have been looked at in the management of CF as patients with CF continue to live longer with the help of newer therapies, the microbiome in the lung becomes less diverse along with increased occurrences for noninfectious causes of airway diseases. Though bronchoscopy has been used in conjunction with other modalities such as computed tomography and sputum induction providing a better understanding of the progression of the disease, it still remains valuable in the diagnosis and management of CF.
Paul, L. (2017). Is Bronchoscopy an Obsolete Tool in Cystic Fibrosis? The Role of Bronchoscopy in Cystic Fibrosis and Its Clinical Use. Journal of Thoracic Disease, 9 (Suppl 10), S1139-S1145. https://doi.org/10.21037/jtd.2017.06.143
Originally published in Journal of Thoracic Disease 2017;9(Suppl 10):S1139-S1145. The original material can be found here.